Strategic Collaboration: Leinco Technologies and Vanderbilt University Medical Center
ST. LOUIS, October 19, 2021 –Leinco Technologies, Inc (Leinco), a leading contract development manufacturing organization (CDMO) and life science tools company, today announced an agreement with Vanderbilt University to grant Leinco exclusive rights to scale up production of antibodies created at Vanderbilt University Medical Center (VUMC), a leader in infectious disease clinical research, diagnostics, therapeutics, and vaccine development. The antibodies target a large portfolio of infectious diseases for further research and diagnostics.
A team led by Dr. James Crowe and Dr. Robert Carnahan at the Vanderbilt Vaccine Center continue to develop novel antibodies to current and emerging infectious diseases. Working with immune cells found in the blood and lymph tissue of human infectious disease survivors, VUMC is able to locate and develop antibodies suitable for use in therapeutics, diagnostics and further discovery. The primary goal of this collaboration is to shorten the time between a new virus discovery and the development of diagnostic or research tools made available to the scientific community worldwide. VUMC and Leinco continue to build on their SARS-CoV-2 (COVID-19) relationship, while making significant investments in infectious disease prevention, research, and development of diagnostic tools.
Wm. Patrick Leinert, President and CEO of Leinco Technologies, Inc. Noted, we are excited to greatly expand our collaboration with Dr. James Crowe’s lab and Vanderbilt University Medical Center to rapidly make their discovery of infectious disease antibodies available for research and diagnostics. This agreement should put us in a better position to provide research tools and diagnostic kit components at a shorter response time making us better able to battle infectious disease outbreaks and future pandemics
Leinco is a leader in infectious disease antibody and antigen manufacturing for use in diagnostic test kits. Their reagent portfolio includes antibodies and antigens related to Influenza, HIV, SARS-CoV-2, Zika, Dengue, Chikungunya, and others. It is Leinco’s goal to aid in the prevention of future public health challenges by making available high purity antibodies and antigens for development of rapid point of care and home-based diagnostic test kits.
As Leinco approaches its 30th year in the life science tools industry, our goal remains the same. Provide the highest purity antibodies and proteins possible and make them widely available to life science researchers and developers of diagnostic test kits. Leinco also manufactures In vivo GOLDTM and In vivo PLATINUMTM antibodies for use in pre-clinical trials. These antibodies have the highest purity standards within the industry. Leinco’s innovative products and services are used to augment the early discovery process in life science research, diagnostics and ground breaking development of biological therapeutics.